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Enterochromaffin-Like Cells
Rod Dimalinea and Andrew J. Baxendale
Physiological Laboratory, University ofLiverpool, Liverpool, United Kingdom
The ability of histamine to stimulate gastric acid secretion was recognized over 75
years ago by Popielski [1]. The central importance ofthis action in the physiological reg-
ulation of acid secretion was established with the development of histamine H2 receptor
antagonists by Black and colleagues in the early 1970s [2]. There has, however, been
intense debate about the precise mechanisms of action, and relative importance of, hista-
mine and the other major gastric acid secretagogues, gastrin and acetylcholine. The cur-
rently favored view proposes that gastrin and acetylcholine act principally by releasing
histamine, which then acts directly on the acid-secreting parietal cell. This idea is sup-
ported by pharmacological studies on histamine H2 antagonists in vivo and in isolated per-
fused stomachs, and by the fact that gastrin and muscarinic agonists release histamine
from the isolated perfused stomach, and increase activation of gastric histidine decar-
boxylase (HDC, EC 4.1.1.22), the enzyme that converts histidine to histamine [3-7].
However, there is also evidence for separate receptors for gastrin, histamine and acetyl-
choline on canine parietal cells [8], suggesting that in some circumstances all three agents
may be able to act directly on this cell type.
Kahlson and colleagues were the first to demonstrate increases in histidine decar-
boxylase (HDC)b activity in rodent gastric mucosa in response to gastrin and cholinergic
agents [4], and it is now well recognized that this response is localized to the enterochro-
maffin-like (ECL) cell [4, 9, 10]. Since ECLcells represent arelatively highproportion of
gastric corpus mucosal endocrine cells in rodents, these species are well suited to studies
ofECLcell function. The relative scarcity ofECLcells in some other species raised ques-
tions about the generality ofthe gastrin-induced increases in HDC activity in this cell type
[10, 11]. Nevertheless, in all species where purified ECL cells have been studied, gastrin-
induced activation of HDC activity has been observed [12-14].
Increases in HDC activity could, in principle, arise by de novo synthesis of enzyme,
or by activation of a pre-existing but inactive enzyme pool, since it is known that HDC
activity can be modulated by phosphorylation [15]. In addition, there exists the possibili-
ty that translation rates are regulated. The opportunity to examine in more detail the reg-
ulation of HDC expression arose with the cloning of a cDNA encoding the enzyme in
1990 [16], and subsequent elucidation ofthe genomic sequence [17, 18].
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PHYSIOLOGICAL REGULATION OF HDC MRNA
ABUNDANCE IN ECL CELLS
HDC mRNA abundance is strongly regulated in vivo by changes in the gastric lumi-
nal environment. Thus, in rats fasted forperiods ofup to 48 hours there was about a four-
fold decrease in corpus HDC mRNA, which was accompanied by a marked reduction of
circulating gastrin concentrations [19, 20] (Figure 1). The depression of gastrin and of
HDC mRNA is probably due largely to the effects of unbuffered gastric acid rather than
withdrawal offood, since it did not occur in animals made achlorhydric by administration
ofthe proton pump inhibitor omeprazole, during the food withdrawal [18, 19] (Figure 1).
The role of gastrin in mediating the responses to luminal pH is supported by the finding
that fasted, achlorhydric animals did not express high levels of HDC mRNA when treat-
ed concomitantly with a specific gastrin/CCK-B receptor antagonist [19]. When rats fed
ad libitum were made achlorhydric there was little further increase in HDC mRNA for
periods of up to 48 hours, suggesting that under normal circumstances gastrin regulates
HDC mRNA over its physiological range of circulating concentrations [19] (Figure 1).
There is, however, a marked progressive increase in HDC mRNA abundance in fed rats
in the face ofchronic hypergastrinaemia induced by prolonged achlorhydria [21, 22].
The fasting-evoked reduction in HDC mRNAdevelops gradually over48 hours, with
significant depression first evident after about 12 hours [20]. In contrast, re-feeding
induced a rapid two-fold upregulation ofHDC mRNA within 30 minutes [20]; thereafter,
there was a gradual sustained increase over the following 48 hours until control levels of
expression were achieved. The rapid response to feeding of HDC mRNA suggests that
there may be functionally important changes in HDC gene expression over the time
course of a single meal. Gastrin modulates, at least in part, the rapid response to feeding
since it was significantly attenuated in animals pre-treated with potent and specific gas-
trin/CCKB-receptor antagonists (Figure 2). Evidence that gastrin is also involved in
mediating the sustained response to feeding is provided by the observation that this
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response was reduced in animals passively immuno-neutralized with gastrin-specific anti-
sera [20]. Moreover, infusion of exogenous gastrin in conscious fasted rats led to eleva-
tion of both HDC activity and mRNA abundance within two hours [23, 24]. But, the
responses to exogenous peptide were slower and of lower magnitude than those elicited
in response tofeeding, suggesting thatotherendogenous factors are involved [23]. Further
evidence for a substantial gastrin-independent component to the feeding response, is pro-
vided by the finding that this response was also significantly reduced by pre-treatment
with the muscarinic antagonsist atropine, in a dose that did not reduce circulating gastrin
concentrations (Figure 3).
REGULATION OF OTHER ECL CELL mRNAS:
THE CO-ORDINATED ECL CELL RESPONSE
While HDC is undoubtedly the key determinant ofhistamine production, there are a
number ofother proteins expressed in ECL cells that are likely to have important roles in
the sequestration and storage ofthe secretory product. Chromogranin A (CGA) is a large,
soluble, acidic protein that in gastric corpus appears to be localized exclusively to ECL
cells and has been used as a marker for them in health and disease [25]. CGA is the
biosynthetic precursor of a number of biologically active peptides, e.g., pancreastatin,
although there appears to be limited processing ofCGA in rat stomach [26]. However, it
has been suggested that CGA may play a role in the condensation ofmaterial during for-
mation of secretory granules of the regulated pathway [27] and may help stabilize the
granule interior in amine secreting cells [28]. In this context, it is, therefore, of interest
that CGA mRNA abundance changed in parallel with that of HDC, in response to both
changes in gastric luminal pH, and to fasting and feeding [29]. One possibility is that the
changes in CGAbiosynthesis reflect aresponse to changes in either the numbers or amine
content of the ECL secretory granules.
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Figure 2. Effect of gastrin antagonists
on HDC mRNA and plasma gastrin
responses to feeding. Groups of six rats
were fasted for 48 hr (water ad lib) then
refed for30 min. One hourbefore feeding,
they received by tail vein injection, vehicle
alone (50pd formamide, 20percent crema-
phor, 80 percent saline; solid bars), or the
gastrin/CCKB antagonist L265,260 (5
mg/kg, hatched bars, upper panel), or the
gastrin/CCKB antagonist GR165800X
([1 mg/kg] hatched bars, center panel) or
the CCKA antagonist devazepide (1
mg/kg, hatched bars, lower panel). HDC
mRNA in gastric corpus was determined
by Northern blot and plasma gastrin by
specific radioimmunoassay [20]. Values
are mean (± SEM, n = 6). * = significantly
different from fasted control P< .05, one-
way ANOVA. # = significantly different
from re-fed vehicle treated group, P< .05.
GR165800X= 2-{3-[-(lH-Indazol-7-yl)-
ureido]-5-methyl-2-oxo-2,3-dihydro-
benzo[e][1,4]diazepin-1-yl)-N-methyl-
N-phenyl-acetamide, isomer 1.
250 -
200 -
150 -
100 -
50-
0 o - 0
0
41 150 -
=
= 100-
5
a0 la 50-
I0
.0
100 -
2
100 -
50 -
0 -
197Dimaline and Baxendale: HDC gene expression
It seems unlikely that ECL cells possess a plasma membrane histamine transporter,
but there is evidence that they can accumulate histidine, possibly utilizing amino acid
transport system N [30], and convert it to histamine in the cytosol [31]. There must exist,
therefore, mechanisms to transport histamine into the secretory granules. In othercomparable
systems, vesicular transporters have been identified specific for acetylcholine, GABAand
biogenic amines [32-35]. A transporter specific for histamine has not yet been identified,
but one ofthe two vesicular monoamine transporters cloned (VMAT2) is able to transport
histamine [36], and anumberoflines ofevidence suggest that itmay function as ahistamine
transporter in the ECL cell. First, there is immuocytochemical evidence for the presence
ofVMAT2 in ECLcells [37]. Second, VMAT2 has been cloned from rat gastric corpus and
identified by Northern blot in ECL cell-enriched fractions of gastric corpus mucosa [22].
Finally, the energy required for transport of amines by VMAT2 is provided by a proton
gradient, and there is direct evidence for such a gradient, generated by aV-typeATPase in
the secretory granule ofthe ECL cell [14]. The affinity for histamine ofVMAT2 is about
10-fold lower that its affinity for otherbiogenic monoamines such as dopamine, serotonin
and noradrenaline [38]. However, ECL cells are normally devoid of serotonin and cate-
cholamines [39, 40], and it seems likely that the high levels ofHDC ensure that histamine
is the only effective substrate accessible to VMAT2.
Unlike HDC, the abundance of gastric corpus VMAT2 mRNA was not affected by
fasting for up to 48 hours, or by subsequent refeeding [22]. It was however elevated sig-
nificantly, like HDC and CGA mRNA, in rats treated with omeprazole for five days to
induce achlorhydria and hypergastrinaemia [22] (Figure 4), suggesting that chronic, but
not acute stimulation of the ECL cell upregulates vesicular monoamine transporters.
Presumably, upregulation ofVMAT2 in response to prolonged hypergastrinaemia secures
48h fastFI
30' refed vehicle
o 300 30' refed atropine E
80
0 ~ ~ ~ ~ ~ ~ ~~~~~~6
200-
40
-0~
2~~~~~~~~~~~~2
0- -~~~~~~~~~0
HDC mRNA Plasma gastrin
Figure 3. Effects ofatropine on HDC mRNAand plasma gastrin responses to feeding. Groups of
six rats were fasted for48 hr (wateradlib) then re-fed for 30 min. One hourbefore feeding animals
received by subcutaneous injection either vehicle alone (saline, hatched bars) or atropine (400
,ug/kg, solidbars). HDC mRNAin gastric corpus was determined by Northen blot andplasma gastrin
by specific radioimmunoassay [20]. Values are mean (± SEM. * = significantly different from control
(fasted) group, P < .05, one-way ANOVA.
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enhanced capacity to efficiently transport the increased cytoplasmic histamine into secretory
granules. The ECL cell responses to hypergastrinaemia are not part of a non-specific
response of gastric corpus mucosa because somatostatin mRNA abundance in the D-cell
for example, was unaffected (Figure 4).
It seems then that on stimulation by gastrin, and perhaps otherendogenous factors, the
ECL cell exhibits a co-ordinated response in which all aspects ofhistamine biosynthesis
and its sequestration and storage in secretory granules are upregulated (Figure 5).
PATHOPHYSIOLOGICAL REGULATION OF HDC mRNAABUNDANCE
When rats are treated with high doses of gastric acid inhibitors for up to two years,
they develop ECLcell hyperplasia, dysplasia and ultimately gastric carcinoid tumors [41].
It is generally agreed that hypergastrinaemia is a key determinant of the pathological
changes induced by achlorhydria [42]. ECL cell hyperplasia is also seen in humans in
response to thehypergastrinaemia associated withlongterm useofprotonpumpinhibitors
such as omeprazole, but progression to carcinoid tumors has not, so far, been documented
[43,44]. This progression is however seen in somepatients withpernicious anemia orwith
gastrinoma; in the latter case, ECLcell carcinoids only occur in association with multiple
endocrineneoplasia (MEN) type-I [44,45]. Both surgicalremovalofthegastric antrum, and
treatment with somatostatin or its analogues (e.g., octreotide) have been used as thera-
peutic strategies to control gastrin-dependent ECL cell growth. [46, 47].
Inpernicious anemiapatients with multiple ECLcell nodules, expressionofHDC and
CGA mRNAs determined by Northern blot of total RNA from endoscopic biopsies, was
greatly elevated within the nodules compared with adjacent corpus mucosa (Table 1).
Following a 72-hour octreotide infusion, both nodule and corpus mucosal HDC was dra-
matically downregulated with an associated reduction of plasma gastrin concentrations;
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Figure 4. The co-ordinated ECL cell response to hypergastrinaemia. Groups of six rats were
treated with omeprazole (400 pmol/kg daily by gavage) for 0, 1 or 5 days. Upper line graph, plasma
gastrin concentrations determined by specific radioimmunoassay [20]. Lower bar chart, mRNA
abundance forHDC, CGA, VMAT2 and somatostatin in gastric corpus determined by Northern blot
[20, 22, 29]. Values are mean (± SEM. * = significantly different from control (untreated) group, P
<.05, one way ANOVA.
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Table 1. HDC and CGA mRNA in human gastric corpus in response to octreotide.
HDC mRNA CGAmRNA Plasma gastrin (pM)
Nodule: Pre-octreotide 100 100 850
Nodule: Post-octreotide 3.5 25 250
Corpus: Pre-octreotide 5.4 15 850
Corpus: Post-octreotide <1 7 250
Samples ofnormal mucosa and nodule were removed by endoscopic biopsy from the gastric corpus
ofapernicious anemia patient, before and after a 72 hr octreotide infusion (25 pg/hr). mRNAabun-
dance was detenmined by Northem blot and expressed relative to pre-infusion levels; plasma gas-
trin was determined by specific radioimmunoassay [20, 29].
CGA was also downregulated, but less markedly (Table 1). It seems possible that the
downregulation by octreotide results from a combination ofinhibitory effects on both the
antralG-cellandtheECLcellitself.Therelatively smallerresponses seenwithCGAcompared
with HDC are perhaps unsurprising given that in rats, CGA is less strongly regulated in
response to changes in gastric luminal pH (and, therefore, somatostatin release) than is
HDC [19, 20, 29]. Determination ofHDC mRNAabundance in biopsies from gastric cor-
pus mucosa and from nodules, may be a useful adjunct to conventional methods for
assessing ECL cell dysfunction in these tissues. In addition, evaluation of the HDC
mRNAresponse to octreotide therapy provides some indication ofthe susceptibility ofthe
nodules toneuroendocrinecontrol.Thisinformation maybeofvalueinpredictingtheoutcome
of more permanent therapeutic strategies such as antrectomy.
CGAS e
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Figure 5. Schematic representation ofhistamine biosynthesis in theECLcell. ChomograninAand
VMAT2 reside in the dense cored secretory granule and its membrane, respectively, after transport
through the regulated pathway of secretion. Cytosolic histamine enters the granule via VMAT2 in
exchange for intragranular protons. The proton gradient is generatedby aV-typeATPase; a chloride
or potassium channel may be present in the granule membrane. HDC, VMAT2 and CGA mRNAs
are upregulated by gastrin; HDC and CGAmRNAs are downregulated by luminal acid, presumably
mediated by somatostatin.
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ECL nodule S Q T P L W R R D G T G H Y L C N A C G L Y S K M N G L S R P L 33
rGATA-6 S Q T P L W R R D G T G H Y L C N A C G L Y S K M N G L S R P L 33
cGATA-6 S Q T P L W R R D G T G [N Y L C N A C G L Y T K M N G L S R P L 33
rGATA-4 A M S T P L W R R D G T G H Y L C N A C G L Y H K M N G N R P L 33
cGATA-5 A M S T P L W R J] D G T G H Y L C N A C G L Y H K M N G N R P L 33
bGATA-3 A T S T P L W R R D G T G H Y L C N A C G L Y H K M N G Q N R P L 33
hGATA-2 A T A T P L W R R D G T G H Y L C N A C G L Y H K M N G Q N R P L 33
hGATA-I A T A T P L W R R DM[T G H Y L C N A C G L Y H K M'N G Q N R P L 33
ECL odule K P Q K R V P S S R R L G L S C A N C H T T T T T L W R R N A E 66
rGATA-6 K P Q K R V P S S R R L G L S C A N C H T T T T T L W R R N A E 66
cGATA-6 K P Q K R V P S S R R L G L S C A N C H T T T T T L W R R N A E 66
rGATA4 K P Qr R L S A S R R V G L S C A N C CM T T T T T L W R R N A E 66
cGATA-5 J K P 0 K R L S S S R R A G L C CD N C H T T MT T L W R R N A E 65
bGATA-3 K P W R L S AA R A G TLC A N C Q TT T T T L W R R N A [F 66
bGATA-2 PK R RL S A A RR IA G TC A N C IT T T T T L W R R N A IN 66
bGATA-1 RJIP RR J LjR G CTC aN C TTT T TTT L W R R N A 66
Figure 6. Cloning ofhuman GATA-6 from an ECL cell nodule. The protein sequence predicted
by cDNA generated by PCR from a human ECL cell nodule is aligned with the corresponding
regions of other members of the GATA family. The human ECL cell sequence is identical with rat
GATA-6, but differs from all other members ofthe family.
GENOMIC REGULATION OF HDC
Examination of molecular mechanisms and intracellular signalling pathways
involved in regulation of the HDC promoter by gastrin have been hampered to some
extent by the lack of a permanent ECL cell line. Wang and colleagues used a poorly dif-
ferentiated gastric cancer cell line (AGS) permanently transfected with the gastrin/CCK-
B receptor to investigate transcriptional activation ofHDC. Using this approach they were
able to demonstrate regulation of the rat and human HDC promoters by gastrin, through
a protein kinase C pathway [18, 48]. In the human promoter, they localized the cis-acting
gastrin response element to downstream of the transcriptional start site and identified a
potentially novel transcription factor that bound to it [48].
In addition, however, expression ofHDC mRNAin ECLcells is regulated by gastrin-
independent mechanisms (see above, Figure 3), and this is also plainly the case in other
histaminergic systems. In this context, itis ofinterest thatthe human HDC promotercontains
a number of canonical cis-acting elements, notably, four GATA consensus sequences of
the type (A/T)GATA(A/G) [17]. The GATAconsensus sequences are recognized by a family
of at least six vertebrate proteins that all contain two zinc finger-binding domains of the
type C-X-N-C-(X17)-C-N-X-C [49, 50]. GATA-1 and GATA-2 are crucial regulators of
hematopoiesis, and GATA-3 is implicated inT-cell development [49, 51]. GATA-4, -5 and
-6 have been proposed to represent adistinct subfamily that may regulate gene expression
in a range of developing tissues including gut epithelium [50, 52, 53].
GATA-4 and GATA-6 have been shown tobind functionally to sequences in the promoter
ofgastric proton pump genes and their mRNAs have been localized by in situ hybridization
to parietal cells [54, 55]. Recently, however, it has also become clear that GATAproteins
are expressed in gastric endocrine cells [56]. Several lines ofevidence are consistent with
the idea that GATA-6 is preferentially located in gastric endocrine cells in general, and in
ECL cells in particular. Thus, GATA-6 mRNA was detected in rat corpus mucosal cells,
enriched with ECL cells by centrifugal elutriation and in an endocrine cell line (STC-1)
derived from mouse gut epithelium [56]. Moreover, when mixed oligonucleotide primers
to a conserved region of the GATA family were used in PCR with a cDNA template
derivedfrom ahuman ECLcell nodule, a single band ofthe appropriate size was obtained.
Cloning and sequencing of the PCR product revealed that it corresponded to human
GATA-6 [56] (Figure 5).
The role of GATA proteins in ECL or other gastric endocrine cells is not yet clear.
However, in gel shift assays, proteins in nuclear extracts from STC-1 cells bound specifically
to the GATA consensus sequence AGATAT, that occurs three times in the human HDCDimaline and Baxendale: HDCgene expression
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HKB40 TGGAGGACAQATI&CACGCAAGCCCCAGCCCTCC
Figure 7. Identification of GATA-
binding factors in the STC-1 cell line.
+ Proteins binding GATA consensus
3 sequences of the human HDC promoter
were identified in STC-1 cells by gel
mobility shift assays [56]. Left panel,
STC-1 cell nuclear protein extracts
bound to a 32P-labelled oligonucleotide
(HDC36) containing the consensus
sequence TGATAA that occurs three
times in the hHDC promoter (lane 1),
and to a labelled oligonucleotide
(HDC24) containing the sequence
AGATAG, that occurs once in hHDC
(lane 2). Right panel, binding of the
labelled oligonucleotide HDC17 to
STC-1 nuclear protein extract. Lane 1,
no extract present; lane 2, protein
extract present; lane 3 protein extract
present together with unlabelled
oligonucleotide (HKB40) correspond-
nCflATG ing to the GATAconsensus region ofthe
HK-ATPase B subunit promoter. Arrows
indicate retardation ofthe labelled probe
induced by protein binding; free
unbound probe appears at the lowerbor-
der of the gel. Sequences of oligonu-
cleotides used in the assays are given
below.
promoter, and to the sequence TGATAA, that occurs once [56] (Figure 7). Furthermore,
expression of GATA-6 mRNA in rat gastric corpus was upregulated by feeding, in concert
with HDC mRNA [56]. GATA transcription factors and GATA-6 in particular, therefore,
have a potential role in physiological regulation of HDC expression . In addition, howev-
er, they maybe involved inregulating developmentofthe gastrointestinal tract. TheGATA-
4, -5, -6 subfamily havebeen linked to control ofdevelopment in a numberofvertebrate tis-
sues, including heart, gut epithelium, primitive endoderm and gonads [50,52,53]. In rat
gastric corpus, GATA-6 and GATA-4 were upregulated at the time of terminal differenti-
ation of the stomach, and the development of its responsiveness to gastric acid secreta-
gogues, raising the possibility that they may play a regulatory role in this process [56].
PERSPECTIVES
The central importance ofthe ECLcell in the physiological regulation ofgastric acid
secretion is now beyond any doubt. Stimulation of the ECL cell, primarily by gastrin,
increases histamine secretion, HDC enzyme activity, and HDC gene expression. Increases
in HDC mRNA abundance in response to feeding are sufficiently rapid to account for
changes in histamine biosynthesis over the time course of a single meal. Expression in
ECLcells, ofothergenes such as CGAandVMAT2, whoseproducts facilitate sequestration
and storage ofhistamine, is also upregulated as part of a coordinated response.
Prolonged hypergastrinaemia in rat or man induces progressive increases in HDC
mRNA abundance and ECL cell hyperplasia. Determination of HDC mRNA in endo-
scopic biopsies may be useful in assessing ECL cell dysfunction. It also provides a means
to evaluate responses to pharmacological and surgical strategies designed to reduce stim-
ulation ofthe ECL cell.
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Elucidation of genomic sequences central to ECL cell function has provided the
opportunity to examine at the molecular level their regulation by gastrin and other agents.
Evidence is now emerging for control of ECL cell function and development by known
regulators such as the GATAproteins, as well as by other novel transcription factors.
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